|
|
 |
January 1, 2013
Alphatec Spine Receives U.S. FDA 510(K) Market Clearance for Two New Products and Receives Japanese Shonin Approval to Begin Marketing Its Novel(R) Peek Lumbar Spinal Spacers
December 17, 2012
Amarin Announces Completion of Dosing in a Fixed-Dose Combination Study With Vascepa(R) and a Leading Statin
December 6, 2012
Amarin Announces $100 Million Non-Equity Financing and Vascepa Sales Force Hiring While Continuing to Assess Strategic Alternatives
December 4, 2012
ChemoFx® Used to Develop Multi-Gene Predictors to Chemotherapy in Breast Cancer
December 3, 2012
Solta Medical and SkinCeuticals Announce Exciting Partnership in Canada: Novel Clear + Brilliant® Perméa™ Laser Technology and Topical Skin Care Regiment for Patients and Clinicians
November 28, 2012
Cadence Pharmaceuticals Announces Settlement of OFIRMEV® (Acetaminophen) Injection Patent Litigation with Perrigo Company
November 28, 2012
Velomedix Receives IDE Approval for Randomized Pilot Trial to Evaluate Rapid Therapeutic Hypothermia in the Management of Acute Myocardial Infarction Patients
November 27, 2012
CardioDx Announces Participation in Landmark NHLBI Trial of Strategies for Assessment of Stable Patients with Symptoms of Coronary Artery Disease
November 15, 2012
CardioDx Announces Data Demonstrating the Clinical Utility of Its Gene Expression Test for Obstructive Coronary Artery Disease in Patients 65 or Older
November 14, 2012
ChemoFx Results Show Differences in Chemoresponse between Optimally and Sub-Optimally Debulked Primary Ovarian Cancers
November 12, 2012
New Study Supports Potential Utility of ChemoFx in Primary Ovarian Cancer
November 7, 2012
Alphatec Spine Completes Asset Acquisition of Irvine, CA-Based Phygen LLC
November 1, 2012
New Study Shows Association between ChemoFx®Results and Recurrence Free Survival
October 23, 2012
New Study Concludes CardioDx Gene Expression Test is Cost Effective for Assessing Patients with Suspected Coronary Artery Disease
October 11, 2012
Longitude Capital pumps $385M into new life sciences fund
October 11, 2012
Longitude Capital Closes Second Life Sciences Fund with $385 Million in Commitments
October 10, 2012
Longitude Capital Beats Target for Fund II, Raises $385M for Biotech, Medtech Deals
October 2, 2012
CardioDx Honored as One of FierceMedicalDevices’ Fierce 15 Most Promising
October 2, 2012
Rosetta, Precision Launch MiRview Mets2 Assay In U.S. Oncology Market
September 27, 2012
Alphatec Spine Receives Board Approval to Acquire Assets of Spine Implant Business
September 18, 2012
Alphatec Spine Releases Alphatec NEXoss(TM) Nanostructure Bio-Active Matrix and Announces the First Patient Implant
September 18, 2012
Aptus Endosystems Receives U.S. FDA Clearance for Thoracic-Length HeliFX™ Aortic Securement System
September 11, 2012
Jazz Pharmaceuticals Announces Issuance of New Formulation Patent for Xyrem®
September 10, 2012
Amarin Announces Notification of Patent Allowance for U.S. Application 13/349,150 Related to Vascepa(TM) and FDA Approved MARINE Indication
September 6, 2012
Amarin Announces Notification of Patent Allowance for U.S. Application 13/284,408 Related to Vascepa(TM) and FDA Approved MARINE Indication
September 6, 2012
Jazz Pharmaceuticals Enters Definitive Agreement to Sell its Women's Health Business to Meda
September 6, 2012
Precision Therapeutics’ ChemoFx® Test Useful in Determining Treatment for Resistant and Recurrent Gynecologic Cancer Patients
September 5, 2012
Amarin Announces Notification of Patent Allowances for U.S. Applications 12/702,889 and 13/349,153 Related to Vascepa(TM) and FDA Approved MARINE Indication
September 4, 2012
Amarin Announces Notification of Patent Allowance for U.S. Application 13/282,145 Related to Vascepa(TM) and FDA Approved MARINE Indication
August 29, 2012
Collegium Pharmaceutical Announces Initiation of Enrollment in Phase 3 Efficacy Study of Oxycodone DETERx® in Subjects with Moderate to Severe Chronic Lower Back Pain
August 28, 2012
Amarin Announces Additional Publication of MARINE Phase 3 Clinical Trial Results in the Journal of Clinical Lipidology
August 27, 2012
Covidien Buys Xanodyne's Drug
August 23, 2012
Alphatec Spine Launches New MIS Device, the BridgePoint(TM) Spinous Process Fixation System
August 15, 2012
Solta Medical and Skinceuticals Announce Groundbreaking Partnership To Bring A Novel Fractional Laser and Topical Skincare Regiment To Clinicians and Patients
August 8, 2012
CardioDx Announces Medicare Coverage for Corus CAD Gene Expression Test for the Diagnosis of Obstructive Coronary Artery Disease
August 7, 2012
Corcept Therapeutics Announces $30 Million Synthetic, Capped Royalty Transaction; Terminates Committed Equity Financing Facility
July 31, 2012
CardioDx’s Corus CAD Gene Expression Test Performs Equally Well in Both Women and Men for the Assessment of Obstructive Coronary Artery Disease, Study Shows
July 31, 2012
CardioDx’s Corus CAD Gene Expression Test Performs Equally Well in Both Women and Men for the Assessment of Obstructive Coronary Artery Disease, Study Shows
July 26, 2012
Amarin Announces FDA Approval of Vascepa(TM) (icosapent ethyl) Capsules for the Reduction of Triglyceride Levels in Adult Patients With Severe Hypertriglyceridemia
July 24, 2012
Amarin Announces Publication of ANCHOR Phase 3 Clinical Trial Results in The American Journal of Cardiology
July 19, 2012
Patient Advocate Foundation and Jazz Pharmaceuticals Announce Partnership for Narcolepsy CareLine
July 09, 2012
Collegium Pharmaceutical Expands its Management Team to Support Continued Development of DETERx® Tamper-Resistant, Extended-Release Opioid Program
July 02, 2012
Amarin Announces Notice of Allowance for Additional US Patent Covering AMR101
July 02, 2012
Corcept Therapeutics Announces Underwritten Public Offering of Common Stock
July 02, 2012
Corcept Therapeutics Commences Public Offering of Common Stock
June 27, 2012
Aptus Endosystems Completes $25 Million Series BB Financing
June 20, 2012
emPower! from PixelOptics Named a 2012 R&D 100 Award Winner
June 15, 2012
Civitas Therapeutics Initiates Phase 2a Clinical Study of CVT-301
June 12, 2012
Jazz Pharmaceuticals Completes EUSA Pharma Acquisition
June 11, 2012
"AWAKEN" Survey Finds Only 50 Percent of Americans Understand Significant Health Impact of Narcolepsy, and Many Physicians Not Comfortable Diagnosing the Sleep Disorder
May 31, 2012
Solta Medical Announces Latest Advance in Fraxel® Laser Technology
May 29, 2012
Amarin Announces US Patent Issuance for AMR101
May 24, 2012
FREEDOM Study Data: Patients Experience Sustained Quality of Life Benefits with More Frequent Home Hemodialysis with the NxStage System One
May 14, 2012
Results from Two Studies Demonstrate the Clinical Utility of CardioDx Gene Expression Test in Patients with Suspected Obstructive Coronary Artery Disease
May 11, 2012
Study Shows NxStage Daily Home Hemodialysis Patients More Likely to Receive Kidney Transplant
May 9, 2012
Life Sciences VCs Confront Difficult Reality in LP Appetites
May 9, 2012
Advice from a VC to startups: Speak no evil about the FDA
May 07, 2012
CardioDx to Present Results from Two Studies Evaluating the Clinical Utility of a Gene Expression Test for Obstructive Coronary Artery Disease
April 26, 2012
Jazz Pharmaceuticals Enters Definitive Agreement to Acquire EUSA Pharma
April 19, 2012
Data demonstrates complementary and beneficial effects of topicals used after fractional laser procedures
April 19, 2012
Solta Medical's Clear + Brilliant™ resurfacing device demonstrates significant reduction of pore count and pore size
April 10, 2012
Corcept Therapeutics Announces National Product Launch of Korlym™ for Patients with Endogenous Cushing’s Syndrome
April 9, 2012
Data Published in Premier Endocrinology Journal shows Korlym™ Provides Significant Clinical Improvement in Patients with Endogenous Cushing’s Syndrome
April 2, 2012
Solta Medical Introduces Liposonix® at AMWC in Monaco and Announces Its Portfolio of Aesthetic Energy Devices Reaches Industry Milestones with More Than 2 Million Procedures Completed Globally
March 20, 2012
Amarin Announces notification of patent allowance for AMR101
March 5, 2012
Jazz Pharmaceuticals Announces Public Offering of Ordinary Shares by Selling Shareholders
February 28, 2012
Alphatec Spine Announces Management Realignment to Prepare Company for Next Phase of Global Growth
February 28, 2012
James Reinstein Appointed President and Chief Executive Officer of Aptus Endosystems
February 22, 2012
Collegium Pharmaceutical Announces Series B Financing and Advancement of Development Program for its DETERx®
February 17, 2012
FDA approves Korlym for patients with endogenous Cushing’s syndrome
February 8, 2012
Longitude Capital Adds Gregory Grunberg
January 24, 2012
Precision Therapeutics Enhances Their Straightforward Approach to Personalizing Cancer Care
January 24, 2012
Jazz Pharmaceuticals plc Announces New Executive Appointments
January 18, 2012
Jazz Pharmaceuticals and Azur Pharma Combine to Create Jazz Pharmaceuticals plc
January 7, 2012
Brett Craig to take over operations at PixelOptics
January 6, 2012
Civitas Therapeutics Announces Positive Results from Clinical Study of CVT-301
January 1, 2012
Closed in 2008, Chelsea company makes comeback
|
|
|
